Scilex Holding Company logo

SCLXWScilex Holding Company

NASDAQ

$0.11

-$0.05 (-34.15%)

Scilex Holding Company (SCLXW) common stock listed on NASDAQ. It is led by Henry H. Ji Ph.D., based in 960 San Antonio Road, Palo Alto, CA, United States, 94303, with about 34 employees. Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

Latest reported SCLXW revenue for 2025-09-30 was $10.6M. Net income was -$257.8M. Revenue was up 6.7% from 2025-06-30 to 2025-09-30.

Use this SCLXW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SCLXW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SCLXW SEC filings page. Lician reads the product cache first so this HTML stays unique to Scilex Holding Company even when a live quote feed is slow.

About Scilex Holding Company

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

SCLXW Key Statistics

Market Cap

$0.00M

Volume

262

Previous Close

$0.16

Day Range

$0.11$0.11

00

EPS

-$0.61

Revenue

$56.59M

Net Income

-$72.81M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

+21.1%

Profit Margin

-128.7%

Employees

34

SCLXW Financials

Annual income statement in USD. Latest reported periods first.

SCLXW annual income statement across FY2024, FY2023, FY2022, FY2021
LineFY2024FY2023FY2022FY2021
Revenue$56.59M$46.74M$38.03M$31.32M
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00
Net Income-$72.81M-$114.33M-$23.36M-$88.42M
EPS (Diluted)-$0.61-$1.28-$0.17-$0.67

Total Assets

$92.95M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$3.27M

Operating Cash Flow

$19.35M

Free Cash Flow

$0.00

Scilex Holding Company Company Information

CEO, President & Executive Chairman
Henry H. Ji Ph.D.
Headquarters
960 San Antonio Road, Palo Alto, CA, United States, 94303
Phone
650 516 4310
IPO / Founded
2021-03-08
Data Updated:

Upcoming Events for SCLXW